The role of IMiDs alone or in combination in prostate cancer

Clinical Genitourinary Cancer

Volumn 10, Issue 3, 2012, Pages 141-146

  Nabhan, Chadi ^a   Petrylak, Daniel P ^b  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b Department of Medicine   (United States)

Author keywords

Castration resistant; Hormone refractory; Lenalidomide; Prostate cancer; Thalidomide

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; PACLITAXEL; PREDNISONE; THALIDOMIDE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CASTRATION RESISTANT PROSTATE CANCER; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DYSPNEA; EDEMA; GASTROINTESTINAL TOXICITY; HUMAN; IN VITRO STUDY; LUNG EMBOLISM; MOLECULAR MECHANICS; MONOTHERAPY; NAUSEA; NEUTROPENIA; PROSTATECTOMY; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; THALIDOMIDE;

EID: 84865008203     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.03.005     Document Type: Review

References (50)

1. A. Jemal, R. Siegel, E. Ward Cancer statistics CA Cancer J Clin 59 2009 225 249
2. W.G. Nelson, A.M. De Marzo, W.B. Isaacs Prostate cancer N Engl J Med 349 2003 366 381 (Pubitemid 36886244)
3. D.R. Berthold, G.R. Pond, F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the tax 327 study J Clin Oncol 26 2008 242 245
4. D.P. Petrylak Hormone-refractory prostate cancer: new horizons Rev Urol 5 suppl 6 2003 S54 S58
5. J.S. de Bono, C.J. Logothetis, A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
6. P.W. Kantoff, C.S. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
7. H. Scher, K. Fizazi, F. Saad Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study J Clin Oncol 30 2012 abstract
8. M.A. Reiter, J. Pfitzenmaier, M. Hohenfellner Immunomodulatory treatment approaches for prostate cancer [in German] Urologe A 48 2009 755 763
9. T.M. Sissung, S. Thordardottir, E.R. Gardner Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer Anti Cancer Agents Med Chem 9 2009 1058 1069
10. C.D. Chen, D.S. Welsbie, C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39 (Pubitemid 38524696)
11. M.E. Taplin, G.J. Bubley, T.D. Shuster Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
12. J.D. Debes, D.J. Tindall Mechanisms of androgen-refractory prostate cancer N Engl J Med 351 2004 1488 1490 (Pubitemid 39315314)
13. H. Bonkhoff Neuroendocrine differentiation in human prostate cancer Morphogenesis, proliferation and androgen receptor status Ann Oncol 12 suppl 2 2001 S141 S144
14. N. Vashchenko, P.A. Abrahamsson Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities Eur Urol 47 2005 147 155 (Pubitemid 40126970)
15. J. Li, C. Yen, D. Liaw PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947 (Pubitemid 27148818)
16. M. Schmitz, G. Grignard, C. Margue Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis Int J Cancer 120 2007 1284 1292
17. G. Pourmand, A.A. Ziaee, A.R. Abedi Role of PTEN gene in progression of prostate cancer Urol J 4 2007 95 100
18. M.M. Shen, C. Abate-Shen PTEN inactivation and the emergence of androgen-independent prostate cancer Cancer Res 67 2007 6535 6538 (Pubitemid 47105495)
19. T. Yoshino, H. Shiina, S. Urakami Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy Clin Cancer Res 12 2006 6116 6124 (Pubitemid 44703777)
20. M. Eisenberger, A. Partin Progress toward identifying aggressive prostate cancer N Engl J Med 351 2004 180 181 (Pubitemid 38886653)
21. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
22. A.L. Harris Antiangiogenesis for cancer therapy Lancet 349 suppl 2 1997 SII13 SII15
23. E. Efstathiou, P. Troncoso, S. Wen Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer Clin Cancer Res 13 2007 1224 1231 (Pubitemid 46424064)
24. H. Li, V. Raia, F. Bertolini Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model BJU Int 101 2008 884 888 (Pubitemid 351347717)
25. J.A. Henry, L. Lu, M. Adams Lenalidomide enhances the anti-cancer activity of docetaxel in in-vitro and in-vivo models of prostate cancer AACR 2010 abstract 28468
26. L. Lu, F. Payvandi, L. Wu The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions Microvasc Res 77 2009 78 86
27. L.M. Ellis, L. Rosen, M.S. Gordon Overview of anti-VEGF therapy and angiogenesis Part 1: angiogenesis inhibition in solid tumor malignancies Clin Adv Hematol Oncol 4 1 2006 suppl 1-10; quz 11-2
28. S.M. Capitosti, T.P. Hansen, M.L. Brown Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer Bioorg Med Chem 12 2004 327 336 (Pubitemid 38064206)
29. I.T. Cavarretta, H. Neuwirt, G. Untergasser The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 Oncogene 26 2007 2822 2832 (Pubitemid 46701444)
30. Q. Wang, D. Horiatis, J. Pinski Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation Prostate 61 2004 253 259 (Pubitemid 39350448)
31. M.J. Drake, W. Robson, P. Mehta An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer Br J Cancer 88 2003 822 827 (Pubitemid 36520866)
32. M.E. Franks, G.R. Macpherson, W.D. Figg Thalidomide Lancet 363 2004 1802 1811 (Pubitemid 38698386)
33. P. Richardson, T. Hideshima, K. Anderson Thalidomide: emerging role in cancer medicine Annu Rev Med 53 2002 629 657 (Pubitemid 34177899)
34. R. Dreicer, E.A. Klein, P. Elson Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer Urol Oncol 23 2005 82 86 (Pubitemid 40616297)
35. R.J. Amato, J. Hernandez-McClain, H. Henary Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate Urol Oncol 27 2009 8 13
36. J.A. Garcia, E.A. Klein, C. Magi-Galluzzi Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma Clin Cancer Res 14 2008 3052 3059
37. W.L. Dahut, J.L. Gulley, P.M. Arlen Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 2004 2532 2539 (Pubitemid 41103740)
38. W.D. Figg, A. Retter, S.M. Steinberg Inhibition of angiogenesis: thalidomide or low molecular weight heparin J Clin Oncol 23 2005 http://www.jco.org
39. W.D. Figg, H. Li, T. Sissung Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer BJU Int 99 2007 1047 1055 (Pubitemid 46587914)
40. Y.M. Ning, J.L. Gulley, P.M. Arlen Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 2070 2076
41. P. Mathew, C.J. Logothetis, P.Y. Dieringer Thalidomide/estramustine/ paclitaxel in metastatic androgen-independent prostate cancer Clin Genitourin Cancer 5 2006 144 149
42. S. Romero, G. Stanton, J. DeFelice Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy Urol Oncol 25 2007 284 290 (Pubitemid 47031002)
43. S.L. Sanborn, J. Gibbons, S. Krishnamurthi Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors Invest New Drugs 27 2009 453 460
44. D. Petrylak, K. Resto-Garces, M. Tibyan A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer J Clin Oncol 27 2009 15S (abstract 5156)
45. P. Mathew, N. Tannir, S.M. Tu A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy Cancer Chemother Pharmacol 65 2010 811 815
46. C. Nabhan, P. Patel, D. Villines Effect of lenalidomide (LEN) on biochemical responses and clinical benefit (CB) as a single agent in chemotherapy-naive castration- resistant prostate cancer (CRPC) J Clin Oncol 30 2012 abstract 128
47. D. Keizman, M. Zahurak, V. Sinibaldi Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study Clin Cancer Res 16 2010 5269 5276
48. X. Huang, Y. Ning, M. Mulquin Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 29 2011 15 (abstract 4574)
49. M. Hussain, M. Smith, C. Sweeney Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial J Clin Oncol 29 2011 15 (abstract 4516)
50. C. Parker, D. Heinrich, J. O'Sullivan Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases J Clin Oncol 30 2012 5 (abstract 8)